Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients
Study Details
Study Description
Brief Summary
This study examines the formation mechanism and patient-related factors of silent cerebral infarcts, whose importance has become increasingly recognized in patients undergoing percutaneous coronary intervention.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This study was produced from the assistant's thesis and was previously accepted as a poster at EuroPCR 2020. We recently completed the full-length article.
This thesis study was supported by Ondokuzmayis University.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Chronic Total Occlusion Chronic total occlusion patients undergoing percutaneous coronary intervention. |
Diagnostic Test: Blood serum Neuron-specific Enolase measurement
The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
|
Non-Chronic Total Occlusion Non-Chronic total occlusion patients undergoing percutaneous coronary intervention. |
Diagnostic Test: Blood serum Neuron-specific Enolase measurement
The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
|
Outcome Measures
Primary Outcome Measures
- Baseline Neuron-specific Enolase (NSE) measurement [NSE blood levels were measured 1-2 hours before the procedure.]
Baseline NSE measurement to exclude non-PCI dependent brain injury. Elevation of >20 ng/ml was considered as silent brain injury. Patients with basal nse elevation were considered as SBI and excluded from the study.
- Silent Brain Injury diagnosis [12-18 hours after percutaneous coronary intervention]
NSE blood levels were measured 12-18 hours after the procedure. Elevation of >20 ng/ml was considered as SBI.
Eligibility Criteria
Criteria
Inclusion Criteria:
- CTO and Non-CTO patients undergoing percutaneous coronary intervention
Exclusion Criteria:
-
baseline NSE elevation
-
acute coronary syndromes or cardiac surgery within 4 weeks
-
patients with a cerebrovascular accident
-
intracranial hemorrhage
-
and head trauma
-
central nervous system tumor
-
degenerative central nervous system disorders and neuroendocrine tumors
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Ondokuzmayis University | Samsun | Turkey |
Sponsors and Collaborators
- Ondokuz Mayıs University
Investigators
- Principal Investigator: Muhammet Uyanık, M.D., Ondokuz Mayıs University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SBI IN CTO INTERVENTION